LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

AstraZeneca PLC ADR

Cerrado

74.94 -2.08

Resumen

Variación precio

24h

Actual

Mínimo

74.65

Máximo

75.07

Métricas clave

By Trading Economics

Ingresos

-162M

1.7B

Ventas

1.3B

15B

P/B

Media del Sector

34.387

71.874

BPA

1.045

Rentabilidad por dividendo

2

Margen de beneficio

11.188

Empleados

94,300

EBITDA

330M

4.4B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+21.45% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.00%

3.03%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

241B

Apertura anterior

77.02

Cierre anterior

74.94

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

AstraZeneca PLC ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 mar 2025, 07:42 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

6 feb 2025, 11:07 UTC

Ganancias

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

6 feb 2025, 07:27 UTC

Ganancias

AstraZeneca Expects Further Sales, Earnings Growth After Results Beat Market Views

17 mar 2025, 14:43 UTC

Charlas de Mercado

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mar 2025, 13:55 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mar 2025, 07:04 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mar 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mar 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mar 2025, 07:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mar 2025, 07:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca Buying EsoBiotec for up to $1B

17 mar 2025, 07:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mar 2025, 07:00 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Buy EsoBiotec

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb 2025, 14:59 UTC

Charlas de Mercado

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 feb 2025, 08:04 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 feb 2025, 11:34 UTC

Adquisiciones, fusiones, absorciones

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb 2025, 11:34 UTC

Adquisiciones, fusiones, absorciones

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb 2025, 11:33 UTC

Adquisiciones, fusiones, absorciones

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb 2025, 11:33 UTC

Adquisiciones, fusiones, absorciones

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb 2025, 11:30 UTC

Adquisiciones, fusiones, absorciones

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 feb 2025, 10:49 UTC

Charlas de Mercado
Ganancias

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 15:18 UTC

Charlas de Mercado

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 feb 2025, 13:24 UTC

Charlas de Mercado

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 feb 2025, 12:01 UTC

Ganancias

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 feb 2025, 11:22 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

6 feb 2025, 11:18 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

6 feb 2025, 11:02 UTC

Charlas de Mercado
Ganancias

AstraZeneca's China Woes Seem Manageable -- Market Talk

6 feb 2025, 07:02 UTC

Ganancias

AstraZeneca Declares Dividend $3.10

Comparación entre iguales

Cambio de precio

AstraZeneca PLC ADR Esperado

Precio Objetivo

By TipRanks

21.45% repunte

Estimación a 12 meses

Media 92.93 USD  21.45%

Máximo 97 USD

Mínimo 88 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

76.51 / 77.21Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.